GSK (LON:GSK) Reaches New 52-Week Low – Here’s What Happened

Shares of GSK plc (LON:GSK) reached a new 52-week low on Wednesday . The company traded as low as GBX 1,274.50 ($16.29) and last traded at GBX 1,284.88 ($16.42), with a volume of 167829328 shares traded. The stock had previously closed at GBX 1,340.50 ($17.13).

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Friday, March 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($23.07).

GSK Trading Down 4.7 %

The firm has a market capitalization of £51.82 billion, a P/E ratio of 20.63, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The stock has a 50-day simple moving average of GBX 1,462.29 and a two-hundred day simple moving average of GBX 1,419.80. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities research analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.

Insider Activity

In related news, insider Wendy Becker bought 536 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were acquired at an average price of GBX 1,515 ($19.36) per share, with a total value of £8,120.40 ($10,376.18). Also, insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.57), for a total value of £1,753,088.09 ($2,240,081.89). Company insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.